Please check your internet connection and try again.
# Durveqtix gene therapy
## Overview
Durveqtix is a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older. It is an adeno-associated virus vector (AAV) serotype 9 (AAV9) carrying a micro-dystrophin gene.
## Primary Indications
Treatment of Duchenne muscular dystrophy (DMD) in ambulatory patients aged 4 years and older.
## Adult Dosing
Not applicable. Durveqtix is indicated for patients aged 4 years and older.
## Pediatric Dosing
The recommended dose is a single intravenous infusion of **1.0 x 10^14 vector genomes per kilogram (vg/kg)**.
## Dose Adjustments
No dose adjustments are specified.
## Contraindications
* History of hypersensitivity to any component of Durveqtix.
* Significant pre-existing conditions (e.g., cardiac or renal impairment) that may affect tolerability.
## Adverse Effects
Common adverse effects include:
* Infusion-related reactions (e.g., fever, nausea, vomiting, fatigue, headache, rash)
* Elevated liver enzymes (ALT, AST)
* Troponin-I elevation
* Development of antibodies to AAV9, which may preclude re-administration.
* Potential for thrombocytopenia.
* Risk of Guillain-Barré syndrome.
## Key Drug Interactions
* **Corticosteroids:** Concurrent use with corticosteroids may increase the risk of adverse effects, particularly liver enzyme elevations. Administration of Durveqtix and corticosteroids should be carefully timed to minimize this risk.
* **Immunosuppressants:** The use of immunosuppressants may alter the immune response to Durveqtix, and their use prior to or during treatment should be carefully considered.
## Monitoring
* **Liver function tests (ALT, AST, bilirubin)**: Monitor at baseline and frequently for at least 3 months post-infusion.
* **Cardiac function:** Monitor electrocardiogram (ECG) and cardiac biomarkers (e.g., Troponin-I) at baseline and for at least 3 months post-infusion.
* **Platelet counts**: Monitor for potential thrombocytopenia.
* **Signs and symptoms of infusion-related reactions**: Monitor closely during and after infusion.
* **Neurological assessment**: Monitor for signs of peripheral neuropathy or Guillain-Barré syndrome.
* **Antibody development**: Assess for the presence of neutralizing antibodies to AAV9.
## Clinical Pearls
* Durveqtix is a one-time treatment. Re-administration is not recommended due to the potential for immune responses that could neutralize the vector and lead to severe adverse reactions.
* Patients should be screened for pre-existing conditions that could increase the risk of adverse events.
* A multi-disciplinary team experienced in gene therapy is essential for managing patients receiving Durveqtix.
* Close monitoring for potential liver toxicity and cardiac events is critical post-administration.
***
*Disclaimer: This information is intended for clinical pharmacists and healthcare professionals. It is essential to consult the most current prescribing information and local institutional protocols for complete details and adherence to regulatory requirements.*
